Abeona TherapeuticsABEO
ABEO
About: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Employees: 136
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
22,275% more call options, than puts
Call options by funds: $3.58M | Put options by funds: $16K
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
16% more funds holding
Funds holding: 55 [Q3] → 64 (+9) [Q4]
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
4.09% more ownership
Funds ownership: 66.38% [Q3] → 70.47% (+4.09%) [Q4]
6% less capital invested
Capital invested by funds: $182M [Q3] → $171M (-$11.2M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
129%
upside
Avg. target
$17
159%
upside
High target
$20
205%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 331 met price target | 205%upside $20 | Buy Maintained | 30 Apr 2025 |
HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 58 / 188 met price target | 129%upside $15 | Buy Reiterated | 24 Mar 2025 |
Oppenheimer Francois Brisebois 27% 1-year accuracy 8 / 30 met price target | 144%upside $16 | Outperform Initiated | 5 Mar 2025 |
Financial journalist opinion
Based on 7 articles about ABEO published over the past 30 days
Positive
Benzinga
6 hours ago
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Abeona Therapeutics Inc.'s ABEO stock traded higher on Wednesday.
Positive
Reuters
1 day ago
US FDA approves Abeona's skin disorder therapy
The U.S. Food and Drug Administration on Tuesday approved Abeona Therapeutics' gene therapy for a rare skin disorder.
Neutral
GlobeNewsWire
1 day ago
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a single treatment with a favorable safety profile - - ZEVASKYN to be available through Qualified Treatment Centers beginning in 3Q 2025 - - Abeona Assist™ patient services program offers personalized support for eligible patients and families throughout their treatment journey with ZEVASKYN - - Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA - - Abeona Therapeutics ® to host conference call today, Tuesday, April 29, 2025, at 8:00 a.m. ET - CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah-skin') (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease.
Neutral
Seeking Alpha
3 days ago
Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +
The 'Undercovered' Dozen highlights 12 lesser-covered stocks, offering investment opportunities and fostering community discussion on their potential. Abeona Therapeutics is seen as a Buy due to promising FDA approvals for pz-cel and UX111, potentially transforming the company with its first commercial products by 2025. Plains GP Holdings offers stable cash flows and high dividends in the volatile energy market, making it a strong buy from Louis Gerard.
Positive
Seeking Alpha
1 week ago
Pz-Cel Has Massive Potential For RDEB Patients
Abeona's pz-cel gene therapy shows the most durable wound healing in RDEB patients with no treatment related severe adverse events. There have been no instances of Squamous Cell Carcinoma. The FDA's previous Complete Response Letter focused on manufacturing and control issues. Since those questions have been answered thoroughly, an approval is likely by April 29th. Pz-cel offers a durable, one-time treatment. This reduces long-term costs compared to VYJUVEK which requires ongoing weekly applications.
Positive
Seeking Alpha
2 weeks ago
Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher
Abeona Therapeutics is poised for significant growth in 2025, with potential FDA approvals for Pz-cel and UX111, driving our Buy rating. Pz-cel, targeting RDEB, shows promising clinical data and commercial prospects, with an expected FDA decision by April 29, 2025. UX111, aimed at MPS IIIA, also holds strong potential, with an FDA decision anticipated by August 18, 2025, and substantial market opportunities.
Neutral
GlobeNewsWire
4 weeks ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
1 month ago
Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Greg Gin – Vice President-Investor Relations and Communications Vish Seshadri – Chief Executive Officer Madhav Vasanthavada – Chief Commercial Officer and Head-Business Development Brian Kevany – Chief Technical Officer Joe Vazzano – Chief Financial Officer Conference Call Participants Kristen Kluska – Cantor François Brisebois – Oppenheimer Ram Selvaraju – H.C. Wainwright David Bautz – Zacks Small Cap Research Operator Greetings.
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., will present at the Leerink Partners Global Healthcare Conference in Miami, Florida on Monday, March 10, 2025 at 3:00 p.m.
Charts implemented using Lightweight Charts™